Source: Annual Congress 2011 - Models of disease and drug actions
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Young, R. Austin, R. Bonnert, E. Cadogan, S. Connolly, P. Gardiner, S. Jordan, M. Lawson, P. Mutch, D. Nicholls, S. Paine, G. Pairaudeau, M. Stocks (Loughborough, United Kingdom). AZD3199: A potent and selective β₂-adrenergic receptor agonist with rapid onset of action. Eur Respir J 2011; 38: Suppl. 55, 1779

Member's Comments

No comment yet.

Related content which might interest you: In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonist Source: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007 In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407 Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007 AZD3199: A fast acting β2-receptor agonist with a long duration of action Source: Annual Congress 2011 - Translational models of disease Year: 2011 The in vitro biology of Compound X – a novel β2 adrenoceptor agonist with a long duration of action Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Unique receptor dissociation kinetics of the novel endothelin receptor antagonist macitentan Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance Source: Annual Congress 2007 - New drugs for COPD Year: 2007 The dual endothelin receptor antagonist bosentan reduces TNFα induced GM-CSF release more effectively than the endothelin A receptor antagonist ambrisentan Source: Annual Congress 2010 - Airway smooth muscle cells Year: 2010 GB001 is a potent, insurmountable DP2 antagonist with long receptor residence time and extended pharmacodynamic effects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist Viozan™ (AR-C68397AA) is well tolerated in a dog model Source: Eur Respir J 2001; 18: Suppl. 33, 406s Year: 2001 Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Ligand independent activation of the glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2004; 24: Suppl. 48, 317s Year: 2004 Vasopressin is involved in endothelin receptor antagonist-induced fluid retention in rat. Differential effect of selective ETA and dual ETA/ETB receptor antagonists Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 A potential role for dissociation rate from the M3 muscarinic receptor in the onset of action of NVA237 and tiotropium Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 PKA/cAMP-independent transactivation of glucocorticoid receptor by long acting β2 agonists Source: Eur Respir J 2006; 28: Suppl. 50, 103s Year: 2006 Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004 The non-prostanoid IP receptor agonist, APD811 (ralinepag) has potent antiproliferative and vasorelaxant properties in human pulmonary artery Source: International Congress 2017 – Experimental PH Year: 2017 Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020 Year: 2020 Phase 1 evaluation of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, a potent and selective blocker of IL-4Ra Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 The novel dual D2 dopamine receptor, β2-adrenoceptor agonist, Viozan™ (AR-C68397AA) improves quality of life and perception of efficacy Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001 Inhibition of cough reflex by D2 receptor agonism with Viozan™ (AR-C68397AA) Source: Eur Respir J 2001; 18: Suppl. 33, 32s Year: 2001